Topoisomerase I-inhibition enhances vitamin D-responsive expression of the receptor for lipopolysaccharide binding protein CD 14.
Pretreatment (4h) of human HL 60 leukemia cells with the topoisomerase I-inhibitor camptothecin (7-28 x 10(-9) Mol/l, single dose) enhanced vitamin D3-responsive CD 14 expression (10(-11)-10(-8) Mol/l vitamin D3) up to twofold, as measured by fluorescence activated flow cytometry after 1-3 days. Camptothecin by itself caused marginal effects. Hybridization of total RNA with oligonucleotides (bases 1358-1333 of CD 14 sequence) showed increased steady state levels of the 1.75 kb CD 14 mRNA after 24 h when normalized to beta-actin. The nuclear accumulation of [3H]-vitamin D3/receptor complexes (VDR) in a nuclear translocation assay was significantly enhanced (by 3 h) in the presence of camptothecin. We conclude that inhibition of topoisomerase I enhances vitamin D3-stimulated CD 14 expression. Topoisomerase I might either be a negatively active transcription factor itself or maintenance of DNA-bending, local supercoiling and accessibility of responsive elements might lead to reduction of VDR turnover and produce a stimulatory effect on vitamin D3-responsive transcription.